EuroMRD ALL KMT2A 2026
EuroMRD ALL KMT2A EQA scheme 2026
Task 5: KMT2A-based RQ-PCR
The section for RQ-PCR based minimal residual disease (MRD) assessment in KMT2A-rearranged acute lymphoblastic leukemia (ALL) is performed once a year. KMT2A-rearrangements serve as RQ-PCR target, and KMT2A-rearranged samples together with the respective KMT2A-rearrangement sequence are provided to participants. Each EQA round consists of one mandatory KMT2A target that is evaluated and scored.
This year, the KMT2A target will be supplemented by a second target based on a PBX1::TCF3 rearrangement, which is known to be a biological driver entity in ALL. This target is not scored, but is included for educational reasons and provides a basis for discussion.
The analysis of MRD data should be undertaken as detailed in the instructions provided by the organizers and in accordance with the EuroMRD guidelines.
Task 5 is issued once per year, starting in 2026 during the spring EQA round.
Performance evaluation and report
Certificates of participation and performance in EQA rounds will be distributed after the EuroMRD meeting of the same calendar year. Performance criteria of the ALL KMT2A scheme: a certificate will be provided if at least 75% of points have been received, otherwise only a certificate of attendance will be provided for this task.
After release of the certificates, participants can submit an appeal if they feel that a mistake was made in the assessment of their performance. If applicable, certificates will be adapted based on received appeals.
EQA Educational meeting
During the ESLHO week in November, the annual EuroMRD meeting is organized. At this meeting, the results of all EuroMRD EQA schemes are shown (pseudonymized) and discussed with all EuroMRD participants, in small discussion groups as well as during plenary sessions.
Registration and participation fee
The EuroMRD ALL KMT2A EQA scheme is only available for participants of the EuroMRD Consortium that are part of the ALL section. The participation fee is € 300. In addition, the EuroMRD annual fee is charged once to every EuroMRD participant.
Organization
The ALL KMT2A EQA scheme is organized by ESLHO (EQA Program Coordinator: Prof. Dr. Jacques J.M. van Dongen) in collaboration with the EuroMRD EQA Committee (ALL KMT2A scheme lead: Dr. Grazia Fazio). The members of the EuroMRD EQA Committee are participants of the EuroMRD Consortium. The EuroMRD subject-matter experts provide support for:
Pre-round: Case selection, determination of consensus results
Post-round: Data analysis, performance evaluation, reporting
Details on the task division can be found below.
Task division
Name | Organization/Institute | Tasks |
|---|---|---|
Dr. Grazia Fazio | Tettamanti Center, Monza, IT | Lead ALL KMT2A scheme |
Dr. Heiko Trautmann, Dr. Britta Kehden | UKSH, Kiel, DE | Coordination of case selection; case selection/providing DNA for PBX1::TCF3 rearranged case; data analysis, reporting; general expert support incl. for results forms, instructions |
Dr. Kerry Wall | Round 1/QA48 (spring): BIR | Case selection/providing DNA for KMT2A rearranged case |
Prof. Dr. Jacques J. M. van Dongen, Dr. Bart Lubbers, Gonny van Muiswinkel, Carla Annink | ESLHO, Zutphen, NL | General coordination, preparation & distribution of wet cases, final responsibility for the scheme |